Neopharm Co., Ltd. · KRX:092730
Neopharm — First Albany Capital Growth Conference 2006
8 slides from Neopharm's conference presentation, Jun 21, 2006
Slide 1: First Albany Capital Growth Conference Annual Meeting of Shareholders
First Albany Capital Growth Conference Annual Meeting of Shareholders June 19, 2006
Slide 2: Safe Harbor Statement
Safe Harbor Statement Various remarks that we may make about future expectations, plans and prospects for the Company constitute forward-looking statements for purposes of the Safe-Harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from
Slide 3: Strategic Vision: Focus and Execution
Strategic Vision “Focus and Execution” Focus on core assets Cintredekin Besudotox (IL13-PE38QQR) NeoLipid® technology platform Prioritize Product Portfolio Fully support Cintredekin Besudotox to ensure success Focus NeoLipid ® on life cycle management Transition to fully integrated biopharmaceutical
Slide 4: Focus on Core Assets: Tumor Targeting Technology IL13-PE38QQR
Focus on Core Assets Tumor Targeting Technology IL13-PE38QQR Enrollment Complete (12/09/05) 294 Patients Enrolled 276 Intent-To-Treat Patients with confirmed first recurrent GBM Primary Endpoint Overall Survival Next Development Milestones Interim Efficacy Analysis – June 2006 Final Efficacy Analysi
Slide 5: Focus on Core Assets: Liposomal Technology
Focus on Core Assets Liposomal Technology Define Target Product Profile Early Focus on Products that support Life Cycle Management Opportunities Assess Product Opportunity Focus on Differentiated Products Market Entry Position (1 st or 2 nd is optimal) Business Development Opportunities Market Poten
Slide 6: Portfolio Optimization
Portfolio Optimization LEP-ETU – Liposomal Paclitaxel Preparing for Phase III via 505(b)(2) pathway Based on non-inferiority with superiority advantage over Taxol ® in breast cancer Potential to be 3 rd new differentiated paclitaxel Taxol ® Patent Expiration = 2000 Approved for ovarian cancer, AIDS
Slide 7: Transition to Fully Integrated Biopharmaceutical Company
Transition to Fully Integrated Biopharmaceutical Company Creation and staffing of commercial entity Head of Regulatory Candidates Identified CFO and CSO searches underway
Slide 8: Strong Fiscal Management
Strong Fiscal Management Short term financing resolved January 2006 Financing 4.0 M shares @ $10.20/share $39.0M proceeds net of discount and underwriting commissions Adequate cash on hand Through 4Q07 April 2006 Cost Rationalization Program Streamlined Research Efforts Strategic investments in comm
Neopharm — First Albany Capital Growth Conference 2006 on 6ix